Secondary prophylaxis after hip fracture. An evaluation og two organisational models based on choise of treatment: a comparison of efficacy and applicability of hospital based treatment with zoledronate versus primary care based treatment with denosumab

Akershus University Hospital, Norway0 个研究点目标入组 500 人开始时间: 2015年3月23日最近更新: 2018年11月19日

适应症

试验速览

暂无简介。

•1. Hip fracture patients 70 years of age or older treated at Akershus University Hospital during one year (365 days) and alive 6 weeks after the fracture. This encompasses also patients 70 years of age or older with a previous hip fracture who suffer a new hip fracture during the 365 days inclusion period
•A hip fracture is defined as a fracture of the neck or the region of the femur. Hip fractures complicated by subtrochanteric fracture or femural shaft fracture are not included in this definition. Other fractures in combination with the hip fracture are allowed.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 500

•1. Patients with estimated life expectancy less than 6 months
•2. Patients unwilling to sign informed consent. Patients with reduced consent capabilities may participate if consent is provided by next of kin or legal guardian
•3. Patients who have suffered allergic og hypersensitivity reactions to treatment with bisphosphonates or denosumab. Patients who have suffered reactions to one medication may partricipate if accepting treatment with the other.
•4. Patients who are permanently bed-ridden.
•5. Patients who due to other disease are not considered candidates for study participation.
•6. Patients with history of osteonecrosis of the jaw or atypical femural fractures.

发起方

Akershus University Hospital, Norway